Kidney-protecting treatment for high-risk upper urinary tract cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to do most daily activities (ECOG 0 to 2).
- Your tumor tests positive for the biomarker HER2 (any level from 0 to 3+).
- You have been diagnosed with high-risk upper urinary tract urothelial cancer on scans and have had a biopsy or brushing sample from the urinary tract.
- Your cancer is considered high-risk (for example, swelling of the kidney from blockage, tumor size ≥2 cm, high-grade tumor, multiple tumors seen in urine tests, or certain past bladder cancer history), and it has not spread to distant organs (M0).
- You need kidney protection now because your kidney function is reduced (eGFR under 60) and you want to protect your kidney.
- You can take study treatment safely: basic blood/clotting tests are acceptable, you’re not pregnant/breastfeeding, and you can avoid certain medicines like steroids and live vaccines around treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oral targeted drug (DV) and an immunotherapy (Toripalimab) to preserve kidney function in people with high-risk upper tract urothelial cancer (UTUC) who cannot have their kidney and ureter removed. It is for patients with only one kidney, reduced kidney function, or cancer in both ureters.
This trial tests a targeted therapy (disitamab vedotin, also called RC48) given directly into the bladder after surgery for HER2-positive upper tract urothelial cancer. The goal is to see if it helps prevent the cancer from coming back.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
This trial tests a combination of an immunotherapy drug (tislelizumab) and a chemotherapy drug (nab-paclitaxel) to treat kidney pelvis cancer while trying to save as much kidney function as possible. It may be an option if you have a small tumor in the kidney pelvis and are scheduled for a laser procedure.
This trial tests a combination of two drugs and radiation therapy given before surgery for high-risk upper tract urothelial cancer. The goal is to see if this approach can improve outcomes for patients who are eligible for surgery.
Hear when a new Upper Urinary Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.